回复6楼:无论是巴西,智利,新加坡,香港,泰国,多米尼加,无论是几千万人还是几百人,得出的结果都一样,中国灭活疫苗有效性不如阿什利康更不如mRNA,这是科学事实.
你想看统计?我给你链接,是自然,柳叶刀的论文,是各国卫生部的统计,都是官网链接:
1,智利卫生部数据,mRNA有效性强于Sinovac
https://www.minsal.cl/las-vacunas-sinovac-y-pfizer-biontech-muestran-en-chile-un-90-y-98-de-efectividad-para-prevenir-el-ingreso-a-uci-respectivamente/
智利卫生部官网,1500万人统计,在2021年1-6月疫苗对防止感染的有效性:
中国Sinovac 63.6%
辉瑞mRNA 90.9%
2,多米尼加数据:两针Sinovac都探测不到对omicron的中和抗体,Sinovac三针相当于mRNA两针
https://news.yale.edu/2022/01/20/vaccine-used-much-world-no-match-omicron-variant
耶鲁大学校报,比较Dominican Republic数据,研究结果在Nature上发表:
https://www.nature.com/articles/s41591-022-01705-6
3,巴西数据,对比中国疫苗和AZ:
https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(21)00150-2/fulltext
柳叶刀论文,7600万巴西疫苗接种后的据统计结果:
AZ疫苗,也就是不如mRNA已经被淘汰的,对预防住院有效率是: 91·4%;ICU是:91.1%;死亡是92.3%
中国CoronaVac疫苗,对预防住院有效率是: 71.2%:ICU是:72.2%;死亡是73.7%
4,泰国论文
https://www.medrxiv.org/content/10.1101/2021.08.27.21262721v1
这是泰国科学家拿中国疫苗和阿斯利康相比,得出的结论,还是不如AZ
When using the anti-SAR-CoV-2 total antibody level(≥132 U/ml) criteria, only 71.3% HCWs in the SV group had seroconversion, compared to 100% in the AZ group.
5,https://pubmed.ncbi.nlm.nih.gov/34820940/
香港论文,Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong
结论:打了第二针一个月后,mRNA抗体比CoronaVac高得多
"BNT162b2 elicited significantly higher antibody avidity levels than CoronaVac."
6,新加坡卫生部部长说,按每10万人的死亡率计算，接种中国产国药疫苗后仍死亡的人数为11；接种科兴疫苗后仍死亡的人数为7.8；接种辉瑞和莫德纳疫苗后仍死亡的人数分别为6.2和1。
https://www.straitstimes.com/singapore/politics/555-of-the-802-covid-19-deaths-in-2021-were-not-fully-vaccinated-ong-ye-kung
而且新加坡卫生部强烈建议打中国两针疫苗的人,加强剂换打信使核糖核酸（mRNA）疫苗,指保护力较佳。
无论是巴西,智利,新加坡,香港,泰国,多米尼加,无论是几千万人还是几百人,得出的结果都一样,中国灭活疫苗有效性不如阿什利康更不如mRNA,这是科学事实.

柳叶刀
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00345-0/fulltext
在防止死亡上三针中国灭活和mRNA疫苗同样有效:97.9%
Between Dec 31, 2020, and March 16, 2022, 13·2 million vaccine doses were administered in Hong Kong's 7·4-million population. We analysed data from confirmed cases with mild or moderate (n=5566), severe or fatal (n=8875), and fatal (n=6866) COVID-19. Two doses of either vaccine protected against severe disease and death within 28 days of a positive test, with higher effectiveness among adults aged 60 years or older with BNT162b2 (vaccine effectiveness 89·3% [95% CI 86·6–91·6]) compared with CoronaVac (69·9% [64·4–74·6]). Three doses of either vaccine offered very high levels of protection against severe or fatal outcomes (97·9% [97·3–98·4]).
灭活疫苗刺突蛋白含量没有mRNA疫苗在体内合成高,需要打第三针加强
加强后,对死亡保护和mRNA疫苗效率一致 97.9%

数据再多，再权威，五毛还是不会信的。他们只相信五毛自己的自媒体新闻。